HTG’s platform is designed for high throughput automation and aids scientists to test any sample, including fixed tissues, without RNA extraction or target amplification.

The array uses qNPA ArrayPlate technology platform, which aids researchers to measure miRNA and messenger RNA (mRNA) simultaneously in the same sample well.

The ArrayPlate technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development.

HTG Molecular Diagnostics Companion Diagnostics and Strategic Marketing senior vice president BJ Kerns said the technology behind the miRNA WTA v16 provides researchers with reproducible and affordable answers to successful signature biomarker discovery programs.